Newfeed

Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts Vector improvements demonstrate broad potential of Replicate’s srRNA for expanded indications in complex infectious disease and in situ expression of therapeutic protein

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: